The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

Symptomatic drug therapy should be initiated when parkinsonian symptoms become bothersome to the patient. L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

U of A researchers have uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug levodopa.

Standard Parkinson's treatment does not always prevent tremors, which affect up to 90 per cent of those with the disease, ...

Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-09-2024, the company has a total of 137.50 Crore shares outstanding.L&T Share Price Today is Rs. 3659.90 as on 03 Jan, 2025, 03:59 PM ...

It is cleared for both children and adults with AADC (aromatic L-amino acid decarboxylase ... and replaces the human dopa decarboxylase (DDC) gene that is mutated in the disease, allowing dopamine ...

Covalent peptide drugs can achieve high potency and selectivity with long dosing intervals, however, methods to discover them are limited. Here, the authors incorporate a genetically encoded ...